Observed Adverse Effects of Sinopharm COVID-19 Vaccine in Healthcare Workers

Khadija Muneer, Nimra Tufail, Muhammad Imran Hassan Khan, Sadia Inam, S. Ayub
{"title":"Observed Adverse Effects of Sinopharm COVID-19 Vaccine in Healthcare Workers","authors":"Khadija Muneer, Nimra Tufail, Muhammad Imran Hassan Khan, Sadia Inam, S. Ayub","doi":"10.21089/njhs.91.0015","DOIUrl":null,"url":null,"abstract":"Abstract: Background: Covid-19 was first identified in Wuhan China in December 2019, and rapidly spread world over. Vaccine was always thought as first line defence against viral infections, and Covid was no exception. Although developed through different technologies, Pakistan got its share of Sinopharm from China and vaccination started in February 2021, with priority for Healthcare workers. There were lot of myths and hesitancy related with the adverse effects and urgency in approving these vaccines. Addressing adverse effects in post vaccinated population hence, became an important matter. Objective: Aim of this study was to observe the adverse effects of this vaccine in Pakistani population, to assess safety and develop confidence in Healthcare Workers. Materials and Methods: A cross-sectional Observation study was carried out in vaccinated Healthcare Professional through Non-probability purposive sampling over a period of one month. A team collected data directly, as well as on the telephone call. A Google form was also generated and sent. Information was collected and analysed on IBM-SPSS 23.0 Result: Majority of the participants were less than 55 years with female dominance. Among co-morbidities, hypertension was most common, followed by diabetes. In local and systemic adverse effects, pain and fatigue were most common, followed by muscle weakness, fever and headache respectively. These effects were also more common after first injection. Conclusion: Results favor that people should be more careful after the first dose as more adverse effects were felt after that. This vaccine has a good safety profile as no major adverse effects were noticed. It was also considered safe for patients with co-morbidities.","PeriodicalId":441304,"journal":{"name":"National Journal of Health Sciences","volume":"103 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"National Journal of Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21089/njhs.91.0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Background: Covid-19 was first identified in Wuhan China in December 2019, and rapidly spread world over. Vaccine was always thought as first line defence against viral infections, and Covid was no exception. Although developed through different technologies, Pakistan got its share of Sinopharm from China and vaccination started in February 2021, with priority for Healthcare workers. There were lot of myths and hesitancy related with the adverse effects and urgency in approving these vaccines. Addressing adverse effects in post vaccinated population hence, became an important matter. Objective: Aim of this study was to observe the adverse effects of this vaccine in Pakistani population, to assess safety and develop confidence in Healthcare Workers. Materials and Methods: A cross-sectional Observation study was carried out in vaccinated Healthcare Professional through Non-probability purposive sampling over a period of one month. A team collected data directly, as well as on the telephone call. A Google form was also generated and sent. Information was collected and analysed on IBM-SPSS 23.0 Result: Majority of the participants were less than 55 years with female dominance. Among co-morbidities, hypertension was most common, followed by diabetes. In local and systemic adverse effects, pain and fatigue were most common, followed by muscle weakness, fever and headache respectively. These effects were also more common after first injection. Conclusion: Results favor that people should be more careful after the first dose as more adverse effects were felt after that. This vaccine has a good safety profile as no major adverse effects were noticed. It was also considered safe for patients with co-morbidities.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在医护人员中观察到的国药集团 COVID-19 疫苗不良反应
摘要:背景:Covid-19 于 2019 年 12 月在中国武汉首次发现,并迅速在全球传播。疫苗一直被认为是抵御病毒感染的第一道防线,Covid 也不例外。虽然是通过不同的技术开发的,但巴基斯坦还是从中国获得了国药集团的份额,并于 2021 年 2 月开始接种,优先接种对象是医护人员。对于这些疫苗的不良反应和批准的紧迫性,人们有很多误解和犹豫。因此,解决接种后人群的不良反应问题就变得非常重要。研究目的本研究旨在观察该疫苗在巴基斯坦人群中的不良反应,评估其安全性并增强医护人员的信心。材料与方法:通过非概率目的性抽样,对接种过疫苗的医护人员进行了为期一个月的横断面观察研究。一个小组直接收集数据,并通过电话收集数据。此外,还制作并发送了一份谷歌表格。收集的信息通过 IBM-SPSS 23.0 进行分析:大多数参与者年龄在 55 岁以下,女性居多。在并发症中,高血压最为常见,其次是糖尿病。在局部和全身不良反应中,疼痛和疲劳最常见,其次分别是肌无力、发烧和头痛。这些不良反应在首次注射后也更为常见。结论结果表明,人们在注射第一针后应更加小心,因为在注射第一针后会出现更多不良反应。这种疫苗的安全性较好,没有发现重大不良反应。它还被认为对合并疾病的患者是安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Observed Adverse Effects of Sinopharm COVID-19 Vaccine in Healthcare Workers Undergraduate Nursing Students’ Satisfaction Level with their Clinical Learning Experiences in Multan, Pakistan Evaluation of the Progress of Coronavirus Disease-19 Pneumonia using the British Society of Thoracic Imaging Reporting Model: A Validation Study Surgical Management of Idiopathic Scrotal Elephantiasis: A Rare Case Report Radiomics: A Powerful Tool
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1